Business context and reporting period
Repligen Corporation (Nasdaq: RGEN) filed this Form 10-K for the fiscal year ended December 31, 2022. It develops and sells bioprocessing technologies used in biologics manufacturing, across filtration, chromatography, process analytics and proteins. The company reports as one business segment. This is an annual filing; the supplied text does not provide a clear standalone fourth-quarter income statement.
Key financial metrics
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $801.5 million | $670.5 million |
| Gross margin | 56.9% | 58.3% |
| Operating income | $224.7 million | $167.2 million |
| Net income | $186.0 million | $128.3 million |
| Diluted EPS | $3.24 | $2.24 |
| Operating cash flow | $172.1 million | $119.0 million |
Cash and cash equivalents were $523.5 million at year-end, with $100.3 million in short-term U.S. Treasury securities. Cash and securities totaled $623.8 million. Cash declined from $603.8 million in 2021; inventory increased to $238.3 million from $184.5 million. Investing activities used $233.2 million, including approximately $88.3 million in capital expenditures, a $45.0 million payment for licensed intellectual property, and $100.0 million invested in Treasury bills.
Convertible senior notes had $287.5 million face value and $284.6 million carrying value, bear 0.375% interest and mature in July 2024. They were classified as current because holders could convert during the first quarter of 2023. Operating lease liabilities totaled $138.3 million. No dividends were paid or planned in the foreseeable future.
Material changes versus prior comparable period
- Revenue increased 19.5% year over year, following 83.1% growth in 2021. Filtration revenue rose to $495.9 million from $403.5 million; chromatography to $131.7 million from $91.0 million; process analytics to $53.5 million from $48.0 million. Protein revenue declined to $114.3 million from $123.7 million.
- Net income increased 45.0% and operating income increased 34.3%. Gross margin fell 1.4 percentage points, with management citing manufacturing headcount, facility capacity costs, depreciation and inflation.
- COVID-19-related revenue was approximately $141 million, or 18% of revenue, versus $190 million, or 28%, in 2021. Management said demand for COVID-19 vaccine-related products was decelerating, while demand in other bioprocessing applications remained robust.
- Operating cash flow increased, but inventory growth used $57.2 million of cash. The company continued substantial capacity investment following acquisitions in 2021.
Outlook, risks and unusual items
Management expects COVID-19-related revenue to decline further in 2023, anticipates a modest increase in R&D spending and higher operating expenses as the business expands, and states existing cash is sufficient for at least 24 months absent acquisitions. No numerical 2023 revenue or earnings guidance is provided in the supplied filing text.
A $28.7 million decrease in the estimated Avitide contingent consideration liability was recorded as a benefit in 2022, compared with $5.9 million of expense in 2021; the liability was $65.5 million at year-end and depends on forecast performance and other significant estimates. Non-GAAP adjusted EBITDA was $246.9 million versus $230.5 million; adjusted net income was $188.6 million versus $175.3 million.
Key risks include competition and product adoption, dependence on limited suppliers for some inputs, manufacturing capacity and supply-chain constraints, acquisition integration and contingent-payment estimates, foreign-exchange exposure (38.2% of 2022 revenue was denominated in foreign currencies), and the continued decline in COVID-related demand. The filing also discloses voluntary self-disclosures to U.S. export authorities concerning potential past export-control violations, which could result in penalties or other consequences. Management and Ernst & Young reported effective disclosure controls and internal control over financial reporting; the financial statements received an unqualified audit opinion.
Important facts for investors to verify
- Whether post-year-end conversions of the 2024 notes, and any resulting cash or share settlement, materially affect liquidity or dilution.
- Whether Avitide meets earnout targets and how changes in forecasts affect the $65.5 million contingent consideration liability and reported earnings.
- How quickly COVID-related sales decline, and whether growth in other product lines offsets that reduction.
- Whether elevated inventory and ongoing capacity investment convert into sales and support recovery in gross margin and cash generation.
- The status and potential financial or operational consequences of the export-control self-disclosures, and any supplier or customer concentration developments.